Open AccessResponses to ALK Inhibitor Treatments in a Patient with Non-Small Cell Lung Cancer Harboring a Novel HPCAL1-ALK Fusion Variant: A Case Report
Author(s) -
Ruixiao Wang,
Jiayue Qin,
Yafeng Fan,
Zhimin Li,
Chongjian Chen,
Wen-Zhong Su
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s252210
Subject(s) - anaplastic lymphoma kinase , fusion gene , lung cancer , cancer research , crizotinib , adenocarcinoma , medicine , alk inhibitor , somatic cell , lymphoma , targeted therapy , fluorescence in situ hybridization , cancer , gene , pathology , biology , genetics , malignant pleural effusion , chromosome
Anaplastic lymphoma kinase ( ALK ) fusion is present in approximately 2-7% of patients with lung adenocarcinoma. ALK fusion-positive patients can benefit from targeted therapy. We herein report a 53-year-old Chinese male patient diagnosed as lung adenocarcinoma with a smoking history. Next-generation sequencing was performed to detect somatic mutations of oncogenic drivers and tumor suppressor genes in plasma-derived circulating tumor DNA using an ultra-deep 160-gene panel. A novel HPCAL1-ALK fusion variant was identified in the patient responding to ALK inhibitor treatments, and the fusion variant was also confirmed by fluorescence in situ hybridization and immunohistochemical. Our study expands the mutational spectrum of ALK fusion variants and provides options for the precise treatment of such patients.